Zhanyu Pan

Zhanyu Pan

Auto-generated profile, based on publicly available information

Zhanyu Pan

Department of Integrated Traditional and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2022 in Phytomedicine
Verified
Journal Article
Closed access
YCYameng Cui
Yameng Cui
YWYulin Wu
Yulin Wu
CWCong Wang
Cong Wang
ZWZuolin Wang
Zuolin Wang
YLYanyang Li
Yanyang Li
ZPZhanyu Pan
Zhanyu Pan

4 September 2017 in Integrative Cancer Therapies
Verified
Journal Article
Open access
CWCong Wang
Cong Wang
PWPeiguo Wang
Peiguo Wang
HOHuaqiang Ouyang
Huaqiang Ouyang
JWJing Wang
Jing Wang
LSLining Sun
Lining Sun
ZPZhanyu Pan
Zhanyu Pan
Objective: To estimate the efficacy of traditional Chinese medicine (Chining decoction, CHIN) for radiation-induced oral mucositis in patients with head and neck cancer. Methods: From May 2014 to December 2015, 70 consecutive patients were randomly assigned to receive CHIN (treatment group) or recombinant human epidermal growth factor (rhEGF) spray (control group) at a 1:1 ratio. CHIN was administered to treatment group from the first day of radiotherapy until the completion of radiotherapy. Simultaneously, the rhEGF spray was administered to control group on the oral mucosa of irradiated area. The clinical benefit was determined by gradation of mucositis (Common Terminology Criteria for Adverse Events v4.0), oral pain, and xerostomia (visual analysis scale) for each week during radiotherapy. Body mass index was evaluated before and after radiotherapy. Results: Patients in the treatment group had prominent remission of oral pain and grade of mucositis on each observing point compared with those in control group ( P < .01). Xerostomia was decreased notably in treatment group compared with control group ( P < .01). Body mass index in the treatment group exhibited advantage over control group after radiotherapy, but there was no statistical significance (19.8 ± 3.26 vs 18.8 ± 2.5 kg/m2, P = .153, >.05). Conclusions: CHIN presented an obvious advantage in preventing radiation-induced oral mucositis compared with rhEGF spray.

26 September 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
XDXianxian Duan
Xianxian Duan
YXYu Xie
Yu Xie
JYJing Yu
Jing Yu
XHXiao Hu
Xiao Hu
ZLZhanzhao Liu
Zhanzhao Liu
YWYue Wang
Yue Wang
Triple-negative breast cancer (TNBC) has the highest percentage of lymphocytic infiltration among breast cancer subtypes, and TNBC patients may benefit from anti-PD-1/PD-L1 immunotherapy. However, some cases whether the immune checkpoint blockade (ICB) shows low targeting efficiency have occurred and effective synergistic targets need to be found, which inspired our exploration of the co-expression analysis of MCT4 (SLC16A3) and PD-L1 (CD274) and their potential regulatory mechanisms. After bioinformatic analysis of the relationship between MCT4 and PD-L1, we validated their positive co-expression relationship in triple-negative breast cancer through multiple immunohistochemical staining (mIHC), CRISPR/Cas9, and lentiviral transduction for MCT4 knockout (sgMCT4/231 KO) or overexpression (pEGFP-N1-MCT4/231). We examined the effect of lactate treatment on PD-L1 expression in triple-negative breast cancer cells by qRT-PCR and Western blot. Combined with our results, we found that MCT4 positively regulated PD-L1 expression through discharging lactate and stabilized PD-L1 through promoting its glycosylation by the classic WNT pathway in MDA-MB-231 cells. More importantly, the high co-expression of MCT4 and PD-L1 appears to predict more effective targets for treating TNBC, which would improve immune checkpoint therapy for TNBC.

1 January 2020 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
BWBin Wang
Bin Wang
JHJin Huang
Jin Huang
SLShanshan Li
Shanshan Li
ZPZhanyu Pan
Zhanyu Pan
YGYongming Guo
Yongming Guo
YGYi Guo
Yi Guo
Objective. As a first‐line treatment for non‐small cell lung cancer (NSCLC), the efficacy of chemotherapy is still unsatisfactory. Moxibustion has been shown to improve the side effects of radiotherapy and chemotherapy and regulate immune function. This study aimed to explore the antitumor effects and potential mechanisms of combinatorial cisplatin and moxibustion treatment for NSCLC by targeting the tumor microenvironment. Methods. Lewis lung cancer (LLC)‐bearing mice were induced and treated with cisplatin or/and moxibustion at ST36 (Zusanli), and the growth, weight, and area of the tumor were evaluated. The numbers of various T cell subsets and myeloid cells in the tumor were assessed by flow cytometry, and the gene expression of related markers and cytokines was detected with real‐time quantitative polymerase chain reaction (RT‐qPCR). In addition, the tumor vascular structure was investigated using CD31 and α‐smooth muscle actin (α‐SMA) immunofluorescence staining. The expression of the vascular endothelial growth factor (VEGF) and hypoxia‐inducible factor‐1α (HIF‐1α) was detected by immunohistochemical staining. Results. Both cisplatin and moxibustion inhibited LLC tumor growth and reduced both the tumor area and weight, with the combinatorial therapy showing superior outcomes. Moxibustion upregulated the infiltration of CD4+ T cells and Th1 cells in the tumor, and the combinatorial therapy increased the proportion of CD8+ cytotoxic T cells (CTLs), CD4+T cells, Th1, Th9 cells, and M1 macrophages, as well as the expression of Cd69, Ifng, and Cd86 mRNA. The combinatorial therapy improved vascular normalization by increasing both the microvessel density (MVD) and pericyte coverage (α‐SMA area density) and inhibiting the expression of the VEGF. Conclusions. Combinatorial cisplatin and moxibustion treatment inhibited the LLC tumor growth by mechanisms related to the improvement of the tumor immune microenvironment and vascular normalization, providing an effective combinatorial therapy beneficial for patients with NSCLC.

12 June 2020 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
YYYinli Yang
Yinli Yang
CWCong Wang
Cong Wang
HSHaiyan Sun
Haiyan Sun
ZJZhansheng Jiang
Zhansheng Jiang
YZYu Zhang
Yu Zhang
ZPZhanyu Pan
Zhanyu Pan

27 April 2023 in Chinese Medical Journal
Verified
Journal Article
Open access
LZLinlin Zhang
Linlin Zhang
LZLili Zeng
Lili Zeng
YSYinjuan Sun
Yinjuan Sun
JWJing Wang
Jing Wang
CWCong Wang
Cong Wang
DZDiansheng Zhong
Diansheng Zhong